Reported Standalone quarterly numbers for Lincoln Pharmaceuticals are:Net Sales at Rs 133.77 crore in December 2022 up 11.58% from Rs. 119.88 crore in December 2021.
Quarterly Net Profit at Rs. 21.61 crore in December 2022 up 22.79% from Rs. 17.60 crore in December 2021.
EBITDA stands at Rs. 33.11 crore in December 2022 up 26.96% from Rs. 26.08 crore in December 2021.
Lincoln Pharma EPS has increased to Rs. 10.79 in December 2022 from Rs. 8.79 in December 2021.
| Lincoln Pharma shares closed at 329.80 on March 13, 2023 (NSE) and has given 9.17% returns over the last 6 months and 5.40% over the last 12 months. |
| Lincoln Pharmaceuticals |
| Standalone Quarterly Results |
in Rs. Cr. |
|
|
Dec’22 |
Sep’22 |
Dec’21 |
| Net Sales/Income from operations |
133.77 |
140.61 |
119.88 |
| Other Operating Income |
— |
— |
— |
| Total Income From Operations |
133.77 |
140.61 |
119.88 |
| EXPENDITURE |
| Consumption of Raw Materials |
47.74 |
51.51 |
40.04 |
| Purchase of Traded Goods |
20.60 |
22.67 |
20.87 |
| Increase/Decrease in Stocks |
-4.42 |
-6.59 |
-5.09 |
| Power & Fuel |
— |
— |
— |
| Employees Cost |
23.44 |
23.03 |
17.07 |
| Depreciation |
2.26 |
2.42 |
2.18 |
| Excise Duty |
— |
— |
— |
| Admin. And Selling Expenses |
— |
— |
— |
| R & D Expenses |
— |
— |
— |
| Provisions And Contingencies |
— |
— |
— |
| Exp. Capitalised |
— |
— |
— |
| Other Expenses |
19.66 |
21.09 |
23.54 |
| P/L Before Other Inc. , Int., Excpt. Items & Tax |
24.49 |
26.49 |
21.27 |
| Other Income |
6.36 |
5.69 |
2.64 |
| P/L Before Int., Excpt. Items & Tax |
30.85 |
32.17 |
23.90 |
| Interest |
0.33 |
0.14 |
0.31 |
| P/L Before Exceptional Items & Tax |
30.52 |
32.03 |
23.60 |
| Exceptional Items |
— |
— |
— |
| P/L Before Tax |
30.52 |
32.03 |
23.60 |
| Tax |
8.90 |
8.32 |
6.00 |
| P/L After Tax from Ordinary Activities |
21.61 |
23.71 |
17.60 |
| Prior Year Adjustments |
— |
— |
— |
| Extra Ordinary Items |
— |
— |
— |
| Net Profit/(Loss) For the Period |
21.61 |
23.71 |
17.60 |
| Equity Share Capital |
20.03 |
20.03 |
20.03 |
| Reserves Excluding Revaluation Reserves |
— |
— |
— |
| Equity Dividend Rate (%) |
— |
— |
— |
| EPS Before Extra Ordinary |
| Basic EPS |
10.79 |
11.84 |
8.79 |
| Diluted EPS |
10.79 |
11.84 |
8.79 |
| EPS After Extra Ordinary |
| Basic EPS |
10.79 |
11.84 |
8.79 |
| Diluted EPS |
10.79 |
11.84 |
8.79 |
| Public Share Holding |
| No Of Shares (Crores) |
— |
— |
— |
| Share Holding (%) |
— |
— |
— |
| Promoters and Promoter Group Shareholding |
| a) Pledged/Encumbered |
| – Number of shares (Crores) |
— |
— |
— |
| – Per. of shares (as a % of the total sh. of prom. and promoter group) |
— |
— |
— |
| – Per. of shares (as a % of the total Share Cap. of the company) |
— |
— |
— |
| b) Non-encumbered |
| – Number of shares (Crores) |
— |
— |
— |
| – Per. of shares (as a % of the total sh. of prom. and promoter group) |
— |
— |
— |
| – Per. of shares (as a % of the total Share Cap. of the company) |
— |
— |
— |
| Source : Dion Global Solutions Limited |
|
